Olin - Winchester Completes Acquisition of Small Caliber Ammunition Manufacturing Assets
The assets, employees and ammunition business are now part of Olin's Winchester Ammunition business, including the brass shellcase capabilities and a newly constructed, world-class, 185,000 square foot production facility located in Manitowoc, Wisconsin. The facility and its skilled employees complement Winchester's existing production capabilities, enabling greater specialization and broader participation across a variety of high-margin, specialty calibers.
Funded from available liquidity, this transaction is expected to be immediately accretive to Olin's shareholders, delivering incremental expected first-year adjusted EBITDA of $10 to $15 million, including synergies realization, leveraging Winchester's industry-leading economies of scale, raw material sourcing, and our projectile, primer, and loading capabilities. Once fully integrated, this acquisition is expected to yield adjusted EBITDA of $40 million per year with full realization of synergies.
"During our recent Investor Day, we committed to our capital allocation framework," said Olin's President and CEO, Ken Lane. "Like the White Flyer acquisition in 2023, this acquisition furthers our Winchester strategy to identify and secure small, bolt-on opportunities that are highly strategic and immediately accretive to Olin. By year three, we expect to have paid one and a half times adjusted EBITDA for these world-class assets."
Brett Flaugher, President of Winchester Ammunition, noted, "The specialization of the Manitowoc facility will expand our reach into higher-value commercial, as well as international military and law enforcement calibers, while deepening our near full integration across the ammunition value chain. This shift enables our larger, legacy plants to focus on high-volume products and growing our cost advantage."
COMPANY DESCRIPTION
Olin Corporation is a leading vertically integrated global manufacturer and distributor of chemical products and a leading U.S. manufacturer of ammunition. The chemical products produced include chlorine and caustic soda, vinyls, epoxies, chlorinated organics, bleach, hydrogen, and hydrochloric acid. Winchester's principal manufacturing facilities produce and distribute sporting ammunition, law enforcement ammunition, reloading components, small caliber military ammunition and components, industrial cartridges, and clay targets.
Visit www.olin.com for more information on Olin Corporation.
FORWARD-LOOKING STATEMENTS
This communication includes forward-looking statements. These statements relate to analyses and other information that are based on management's beliefs, certain assumptions made by management, forecasts of future results, and current expectations, estimates and projections about the markets and economy in which we and our various segments operate. The statements contained in this communication that are not statements of historical fact may include forward-looking statements that involve a number of risks and uncertainties.
We have used the words "anticipate," "intend," "may," "expect," "believe," "should," "plan," "outlook," "project," "estimate," "forecast," "optimistic," "target," and variations of such words and similar expressions in this communication to identify such forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the Company's anticipated financial and other benefits of our acquisition of the ammunition assets of Ammo, Inc. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions, which are difficult to predict and many of which are beyond our control. Therefore, actual outcomes and results may differ materially from those matters expressed or implied in such forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of future events, new information or otherwise. The payment of cash dividends is subject to the discretion of our Board of Directors and will be determined in light of then-current conditions, including our earnings, our operations, our financial conditions, our capital requirements and other factors deemed relevant by our Board of Directors. In the future, our Board of Directors may change our dividend policy, including the frequency or amount of any dividend, in light of then-existing conditions.
The risks, uncertainties and assumptions involved in our forward-looking statements, many of which are discussed in more detail in our filings with the SEC, including without limitation the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2024, and our Quarterly Reports on Form 10-Q and other reports furnished or filed with the SEC, include, but are not limited to, the following:
Business, Industry and Operational Risks
sensitivity to economic, business and market conditions in the United States and overseas, including economic instability or a downturn in the sectors served by us;
declines in average selling prices for our products and the supply/demand balance for our products, including the impact of excess industry capacity or an imbalance in demand for our chlor alkali products;
unsuccessful execution of our operating model, which prioritizes Electrochemical Unit (ECU) margins over sales volumes;
failure to control costs and inflation impacts or failure to achieve targeted cost reductions;
our reliance on a limited number of suppliers for specified feedstock and services and our reliance on third-party transportation;
availability of and/or higher-than-expected costs of raw material, energy, transportation, and/or logistics;
the occurrence of unexpected manufacturing interruptions and outages, including those occurring as a result of labor disruptions and production hazards;
exposure to physical risks associated with climate-related events or increased severity and frequency of severe weather events;
the failure or an interruption, including cyber-attacks, of our information technology systems;
risks associated with our international sales and operations, including economic, political or regulatory changes;
failure to identify, attract, develop, retain and motivate qualified employees throughout the organization and ability to manage executive officer and other key senior management transitions;
our inability to complete future acquisitions or joint venture transactions or successfully integrate them into our business;
adverse conditions in the credit and capital markets, limiting or preventing our ability to borrow or raise capital;
weak industry conditions affecting our ability to comply with the financial maintenance covenants in our senior credit facility;
our indebtedness and debt service obligations;
the effects of any declines in global equity markets on asset values and any declines in interest rates or other significant assumptions used to value the liabilities in, and funding of, our pension plans;
our long-range plan assumptions not being realized, causing a non-cash impairment charge of long-lived assets;
Legal, Environmental and Regulatory Risks
changes in, or failure to comply with, legislation or government regulations or policies, including changes regarding our ability to manufacture or use certain products and changes within the international markets in which we operate;
new regulations or public policy changes regarding the transportation of hazardous chemicals and the security of chemical manufacturing facilities;
unexpected outcomes from legal or regulatory claims and proceedings;
costs and other expenditures in excess of those projected for environmental investigation and remediation or other legal proceedings;
various risks associated with our Lake City U.S. Army Ammunition Plant contract and performance under other governmental contracts; and
failure to effectively manage environmental, social and governance (ESG) issues and related regulations, including climate change and sustainability.
All of our forward-looking statements should be considered in light of these factors. In addition, other risks and uncertainties not presently known to us or that we consider immaterial could affect the accuracy of our forward-looking statements.
2025-10
View original content to download multimedia:https://www.prnewswire.com/news-releases/olin--winchester-completes-acquisition-of-small-caliber-ammunition-manufacturing-assets-302432617.html
SOURCE Olin Corporation

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Taiwan Dollar Strength Tests TSMC Amid AI Chip Boom
TSMC's (NYSE:TSM) finance chief Wendell Huang says currency swings are giving him headaches. He admits a stronger Taiwan dollar can wipe out revenue, so the team is selling spot dollars, locking in forward contracts and parking cash offshore to soften the blow. After a blockbuster second quarter with profit up sixty percent, they still worry that a 1% rise in the local currency cuts reported NT dollar revenue by the same amount. That led to a ten billion dollar investment in an overseas hedging unit. The capital spending plan of $38 to $42 billion dollars remains intact, even as TSMC presses ahead with its Arizona fabs. The second plant could start making chips as soon as twenty twenty?seven, helping to balance out any forex tremors. Investors will be watching the next earnings report for proof that these hedges and overseas expansions can really keep margins on track. This article first appeared on GuruFocus.
Yahoo
an hour ago
- Yahoo
2 Cash-Producing Stocks for Long-Term Investors and 1 Facing Challenges
A company that generates cash isn't automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not all companies are created equal, and StockStory is here to surface the ones with real upside. Keeping that in mind, here are two cash-producing companies that leverage their financial strength to beat the competition and one best left off your watchlist. One Stock to Sell: Columbia Sportswear (COLM) Trailing 12-Month Free Cash Flow Margin: 8.6% Originally founded as a hat store in 1938, Columbia Sportswear (NASDAQ:COLM) is a manufacturer of outerwear, sportswear, and footwear designed for outdoor enthusiasts. Why Do We Think COLM Will Underperform? Constant currency revenue growth has disappointed over the past two years and shows demand was soft Projected sales for the next 12 months are flat and suggest demand will be subdued Waning returns on capital imply its previous profit engines are losing steam Columbia Sportswear's stock price of $59.69 implies a valuation ratio of 16.8x forward P/E. Check out our free in-depth research report to learn more about why COLM doesn't pass our bar. Two Stocks to Watch: (BILL) Trailing 12-Month Free Cash Flow Margin: 22.3% Started by René Lacerte in 2006 after selling his previous payroll and accounting software company PayCycle to Intuit, (NYSE:BILL) is a software as a service platform that aims to make payments and billing processes easier for small and medium-sized businesses. Why Do We Like BILL? Billings growth has averaged 15.3% over the last year, indicating a healthy pipeline of new contracts that should drive future revenue increases Prominent and differentiated software leads to a stellar gross margin of 84.5% Well-designed software integrates seamlessly with other workflows, enabling swift payback periods on marketing expenses and customer growth at scale At $45.98 per share, trades at 3x forward price-to-sales. Is now the time to initiate a position? Find out in our full research report, it's free. Paycom (PAYC) Trailing 12-Month Free Cash Flow Margin: 20.1% Founded in 1998 as one of the first online payroll companies, Paycom (NYSE:PAYC) provides software for small and medium-sized businesses (SMBs) to manage their payroll and HR needs in one place. Why Are We Fans of PAYC? Software is difficult to replicate at scale and leads to a best-in-class gross margin of 85.9% User-friendly software enables clients to ramp up spending quickly, leading to the speedy recovery of customer acquisition costs Healthy operating margin of 27.9% shows it's a well-run company with efficient processes Paycom is trading at $229.71 per share, or 6.2x forward price-to-sales. Is now a good time to buy? See for yourself in our full research report, it's free. High-Quality Stocks for All Market Conditions When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that's already erased most losses. Don't let fear keep you from great opportunities and take a look at Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Insider
3 hours ago
- Business Insider
UnitedHealth Stock Collapse Continues: Here's What This Investor Thinks Will Happen Next
UnitedHealth (NYSE:UNH) is coming off another bruising week, with shares down 7% – bringing the 12-month decline to a steep 50% – as a string of PR crises continues to weigh heavily on investor sentiment. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Since the assassination of Brian Thompson, the CEO of its insurance division, in New York last year, the company has faced mounting scrutiny. Investors are increasingly uneasy about UnitedHealth's transparency, while the public has raised sharp concerns over its claims-handling practices. Given the reputational setbacks, investor A.J. Button believes the fallout could soon weigh on the company's bottom line. 'Bad PR can lead to brand damage,' he warns, 'which in turn can lead to policyholders taking their business elsewhere.' That said, Button acknowledges that the company's fundamentals remain relatively strong. UNH still boasts a robust balance sheet and solid profitability metrics, suggesting it has the financial strength to withstand pressure. 'Nevertheless,' Button cautions, 'the issues facing UnitedHealth right now are very real.' One of the most pressing red flags is the company's exceptionally high claim denial rate, reportedly the highest in the sector, according to multiple sources. While not catastrophic in itself, such a pattern could indicate flawed underwriting or strained claims infrastructure – issues that compound the reputational damage and hint at possible internal mismanagement. 'So,' Button adds, 'UnitedHealth has many qualities, good and bad.' On one hand, its financial footing and history of profitability provide a cushion. On the other, cracks are beginning to show: for fiscal 2024, its combined ratio hit 97.2% – right up against the industry's red line. Button argues that, before investors can have full confidence, the company needs to take meaningful action to shore up its underwriting performance. Whether that turnaround is underway remains an open question. UnitedHealth recently reinstated former CEO Stephen Helmsley, following the previous leader's departure. But the move has raised eyebrows, given that Helmsley is a longtime insider who presided over many of the company's earlier challenges. His return doesn't exactly scream transformation. A rebound is still possible – especially if the company takes decisive steps to restore trust and address internal inefficiencies. However, given the scale of its current controversies, Button advises investors to weigh the risks carefully. Even the stock's seemingly low P/E ratio doesn't present a compelling bargain relative to peers in the life and health insurance space. 'When considering a stock like UnitedHealth, with a good track record but an unprecedented new set of risk factors, it pays to be cautious,' the investor summed up. Can UnitedHealth Stock Bounce Back? Button assigns a 'low-conviction' buy rating on UNH shares – a nod to its potential, but with more than a few strings attached. (To watch Button's track record, click here) Wall Street, though, is a bit more upbeat. The stock holds 19 Buy recommendations, 6 Holds, and just 1 Sell, translating to a Moderate Buy consensus rating. With an average price target of $364.96, analysts are eyeing 29% upside from current levels. (See UNH stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.